Thelansis

Barth Syndrome Market Outlook Thelansis’s “Barth Syndrome Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Barth Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajectory? What insights do in...

Barth Syndrome Market Outlook Thelansis’s “Barth Syndrome Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Barth Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Barth Syndrome Overview Barth syndrome is a rare X-linked genetic disorder that has distinct characteristics, including cardiomyopathy (CM), skeletal myopathy, growth delay, neutropenia, and elevated urinary levels of 3-methylglutaconic acid (3-MGCA). This condition arises from mutations in the TAZ gene (at Xq28), which encodes Taz1p acyltransferase, an enzyme crucial for cardiolipin metabolism—a major phospholipid in the inner mitochondrial membranes. Dysfunct...

 Barth syndrome (BTHS) is a rare X-linked genetic disorder that has distinct characteristics, including cardiomyopathy (CM), skeletal myopathy, growth delay, neutropenia, and elevated urinary levels of 3-methylglutaconic acid (3-MGCA). This condition arises from mutations in the TAZ gene (at Xq28), which encodes Taz1p acyltransferase, an enzyme crucial for cardiolipin metabolism—a major phospholipid in the inner mitochondrial membranes. Dysfunctional Taz1p leads to abnormal cardiolipin remodeling, compromising the integrity of mitochondrial structure and respiratory chain function. Clinical manifestations encompass a broad spectrum, with varying combinations of the following features: dilated cardiomyopathy (DCM), left ventricular non-compaction (LVNC), endocardial fibroelastosis (EFE), hypertrophic cardiomyopathy (HCM), ventricular arrhythmia, sudden cardiac death, neutropenia (ranging from absent to severe), delayed motor milestones, proximal myopathy, lethargy, fatigue, prolonge...

  Barth syndrome (BTHS) is widely recognised as a rare X-linked genetic disease characterised by cardiomyopathy (CM), skeletal myopathy, growth delay, neutropenia, and increased urinary excretion of 3- methylglutaconic acid (3-MGCA). Clinical features include variable combinations of the following wide spectrum: dilated cardiomyopathy (DCM), left ventricular non-compaction (LVNC), endocardial fibroelastosis (EFE), hypertrophic cardiomyopathy (HCM), ventricular arrhythmia, sudden cardiac death, neutropenia (absent to severe; persistent, delayed motor milestones, proximal myopathy, lethargy and fatigue, prolonged QTc interval, failure to thrive, compensatory monocytosis, recurrent bacterial infection, hypoglycaemia, feeding problems, growth and pubertal delay, lactic acidosis, intermittent or perfectly cyclical), episodic diarrhoea, characteristic facies, and X-linked family history. The mean age at diagnosis of BTHS was 4 to 5 years, although the age of onset of symptoms wa...